|
Name |
2,4,6-Cycloheptatrien-1-one, 2-hydroxy-3-(1-methylethyl)-
|
Molecular Formula | C10H12O2 | |
IUPAC Name* |
2-hydroxy-3-propan-2-ylcyclohepta-2,4,6-trien-1-one
|
|
SMILES |
CC(C)C1=C(C(=O)C=CC=C1)O
|
|
InChI |
InChI=1S/C10H12O2/c1-7(2)8-5-3-4-6-9(11)10(8)12/h3-7H,1-2H3,(H,11,12)
|
|
InChIKey |
TUFYVOCKVJOUIR-UHFFFAOYSA-N
|
|
Synonyms |
alpha-Thujaplicin; 1946-74-3; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-3-(1-methylethyl)-; 6TU33PGY8A; 2-hydroxy-3-propan-2-ylcyclohepta-2,4,6-trien-1-one; CHEMBL1275969; thujaplicin; .alpha.-Thujaplicin; 3-Isopropyltropolone; 38094-79-0; UNII-6TU33PGY8A; SCHEMBL355645; 2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one; DTXSID70173098; ZINC2041733; BDBM50330793; AKOS025402371; AC-8489; 2-hydroxy-3-isopropyl-cyclohepta-2,4,6-trien-1-one; 2-hydroxy-3-(propan-2-yl)cyclohepta-2,4,6-trien-1-one; 3IT
|
|
CAS | 1946-74-3 | |
PubChem CID | 80297 | |
ChEMBL ID | CHEMBL1275969 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 164.2 | ALogp: | 2.1 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 37.3 | Aromatic Rings: | 1 |
Heavy Atoms: | 12 | QED Weighted: | 0.692 |
Caco-2 Permeability: | -4.382 | MDCK Permeability: | 0.00002980 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.018 |
30% Bioavailability (F30%): | 0.148 |
Blood-Brain-Barrier Penetration (BBB): | 0.633 | Plasma Protein Binding (PPB): | 89.75% |
Volume Distribution (VD): | 0.574 | Fu: | 10.97% |
CYP1A2-inhibitor: | 0.861 | CYP1A2-substrate: | 0.93 |
CYP2C19-inhibitor: | 0.356 | CYP2C19-substrate: | 0.792 |
CYP2C9-inhibitor: | 0.292 | CYP2C9-substrate: | 0.719 |
CYP2D6-inhibitor: | 0.083 | CYP2D6-substrate: | 0.401 |
CYP3A4-inhibitor: | 0.041 | CYP3A4-substrate: | 0.362 |
Clearance (CL): | 2.882 | Half-life (T1/2): | 0.746 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.025 |
Drug-inuced Liver Injury (DILI): | 0.354 | AMES Toxicity: | 0.217 |
Rat Oral Acute Toxicity: | 0.56 | Maximum Recommended Daily Dose: | 0.037 |
Skin Sensitization: | 0.601 | Carcinogencity: | 0.424 |
Eye Corrosion: | 0.03 | Eye Irritation: | 0.947 |
Respiratory Toxicity: | 0.695 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002874 | 0.692 | D0A3HB | 0.500 | ||||
ENC000365 | 0.553 | D06GIP | 0.419 | ||||
ENC000191 | 0.425 | D06IXT | 0.368 | ||||
ENC001315 | 0.409 | D0N0OU | 0.349 | ||||
ENC000028 | 0.385 | D07HBX | 0.341 | ||||
ENC002809 | 0.360 | D0LG8E | 0.327 | ||||
ENC000033 | 0.357 | D00HHS | 0.327 | ||||
ENC000166 | 0.357 | D0P6UB | 0.313 | ||||
ENC000347 | 0.356 | D09JUG | 0.310 | ||||
ENC000179 | 0.350 | D03GET | 0.308 |